Enterome SA logo

Enterome SA

Enterome is developing innovative therapeutic solutions in the new and promising field of diseases associated with abnormalities of the gut microbiome. ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.enterome.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
94/96 avenue Ledru-Rollin 75011
paris
France
Email
Contact Number
+33 1 75 77 27 85

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; and Bristol-Myers Squibb in immuno-oncology.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/enterome” connections=”true” suffix=””]

Enterome has Two complementary metagenomic platforms for a full genomic and functional analysis of the microbiome. A Quanitative Metagenomics platform, which enables the identification of biomarkers and of bacteria of interest associated with the development of diseases, and the Functional Metagenomics platform, which is based on the screening of genomic that allows the discovery and the development of new drugs and targets.

Recent studies suggest that the gut microbiome plays an important role in modulating mechanisms of response and resistance to cancer immunotherapies.

In Jan 2018, Enterome raised ‹32 Mn in a Series D financing. Seventure, Health for Life Capital, LundbeckFonden Ventures, Omnes Capital and Nestl_ Health Science – participated in the round, alongside new venture investor Principia SGR and strategic investor Bristol-Myers Squibb. Since its establishment, Enterome has raised approx ‹63.5Mn in four roundes of funding.